Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreAlfa Cytology is dedicated to providing chronic lymphoblastic leukemia (CLL) modeling services that enable customers to design, develop, and screen animal models exhibiting phenotypes similar to human CLL. The provided model will serve as a valuable resource for your CLL research. Selecting an appropriate animal model is a pivotal approach to studying the molecular mechanisms underlying CLL pathogenesis and facilitating the development of novel targeted therapies. Our modeling technology enables us to create CLL models that closely resemble the natural environment of the human body.
Several animal models of CLL have been described thus far, with mice being the most commonly utilized model, similar to other types of leukemia. One of the earliest CLL mouse models is the spontaneous New Zealand black (NZB) mouse model, which exhibits clonal proliferation of aneuploid CD5+ B lymphocytes. Alongside this spontaneous model, several transgenic models have been developed, such as the TCL1 transgenic model and the TRAF2DN/BCL2 double transgenic model. Additionally, the xenotransplantation model has shown promising preliminary results, making it a valuable tool for future preclinical efficacy studies of new drugs.
Fig. 1. Timeline of human vs murine studies. (Ten Hacken, E. et al., 2022)
Animal models are important in CLL research because they help to understand the pathogenesis of the disease and to test therapies. Alfa Cytology provides various animal model development services for CLL, including but not limited to the following.
We offer the New Zealand Black (NZB) mouse model, a well-established spontaneous CLL model in which mice develop the disease naturally as they age. Our CLL spontaneous model screening services are provided to support your research into understanding the natural pathogenesis of CLL.
We cloned the human TCL1 gene into animals, resulting in a high level of restricted expression of B cells. The gene is up-regulated in many B-cell malignant tumors and is used to mimic CLL.
In order to study refractory CLL, we offer the Bcl-2/TRAF2DN double transgenic model. This model involves the simultaneous overexpression of Bcl-2 and dominant inactivation of TRAF2 in mice. It serves as an excellent tool for investigating refractory CLL.
Through the utilization of CRISPR-Cas9 technology, we specialize in the establishment of transgenic animal models specifically designed for CLL research. These CLL models serve as valuable tools in identifying potential drug targets for leukemia and improving treatment strategies for the disease. Below, we present a list of available CLL model builds that we offer to support your research endeavors.
With our extensive experience in building xenotransplantation models, we can effectively address your challenges in constructing CLL xenotransplantation models. We offer CLL xenotransplantation model construction services that involve the isolation of CLL-derived cell lines and the utilization of cutting-edge technology.
We offer a co-cultured and conditioned medium model system for CLL, designed to simulate its microenvironment and facilitate the study of the relationship between signal transduction of CLL cells and the surrounding microenvironment. This model system allows for a comprehensive examination of the intricate interactions within the CLL microenvironment.
Alfa Cytology is the most experienced biomedical company in the animal model design industry, focusing on the construction of animal models of leukemia and providing customers with CLL animal models. We provide custom model services with standardized procedures and oversight Please contact us if you need more information about our services in CLL animal models.
Reference